Analysis of van der Waals surface area properties for human ether-a-go-go-related gene blocking activity: Computational study on structurally diverse compounds

SAR and QSAR in Environmental Research

Volumn 23, Issue 5-6, 2012, Pages 521-536

  Moorthy, N S H N ^a   Ramos, M J ^a   Fernandes, P A ^a  

^a Campus Universitário de Santiago   (Portugal)

Author keywords

human ether a go go related gene; hydrophobicity; pharmacophore; quantitative structure activity relationship; van der Waals surface

Indexed keywords

ETHERS; GENES; HYDROGEN; HYDROGEN BONDS; MOLECULES; PHARMACODYNAMICS; SURFACE ANALYSIS; VAN DER WAALS FORCES;

BLOCKINGS; CARDIOTOXICITY; COMPUTATIONAL STUDIES; HUMAN ETHER-A-GO-GO-RELATED GENE; PHARMACOPHORES; PROPERTY; QUANTITATIVE STRUCTURE ACTIVITY RELATIONSHIP; SURFACE AREA; VAN DER WAAL; VAN DER WAAL SURFACE;

HYDROPHOBICITY;

EID: 84864688102     PISSN: 1062936X     EISSN: 1029046X     Source Type: Journal    
DOI: 10.1080/1062936X.2012.666264     Document Type: Article

References (35)

1. Zhu, BY, Jia, ZJ, Zhang, P, Su, T, Huang, W, Goldman, E, Tumas, D, Kadambi, V, Eddy, P, Sinha, U, Scarborough, RM and Song, Y. 2006. Inhibitory effect of carboxilic acid group on hERG binding. Bioorg. Med. Chem. Lett., 16: 5507-5512.
2. Jamieson, C, Moir, EM, Rankovic, Z and Wishart, G. 2006. Medicinal chemistry of hERG optimization: Highlights and Hang-ups. J. Med. Chem., 49: 5029-5049.
3. Sanguinetti, MC and Mitcheson, JS. 2005. Predicting drug-hERG channel interactions that cause acquired long QT syndrome. TRENDS Pharmacol. Sci., 26: 119-124.
4. Brown, AM. 2004. Drugs. hERG and sudden death. Cell Calcium, 35: 543-547.
5. Choe, H, Nah, KH, Lee, SN, Lee, HS, Lee, LS, Jo, SH, Leem, CH and Jang, YJ. 2006. A novel hypothesis for the binding mode of hERG channel blockers. Biochem. Biophys. Res. Comm., 344: 72-78.
6. Perry, M, de Groot, MJ, Helliwell, R, Leishman, D, Tristani-Firouzi, M, Sanguinetti, MC and Mitcheson, J. 2004. Structural determinants of hERG channel block by Clofilium and Ibutilide. Mol. Pharmacol., 66: 240-249.
7. Du, L, Li, M, You, Q and Xia, LA. 2007. A novel structure-based virtual screening model for the hERG channel blockers. Biochem. Biophys. Res. Comm., 355: 889-894.
8. Du, LP, Tsai, KC, Li, MY, You, QD and Xia, L. 2004. The pharmacophore hypotheses of I(Kr) potassium channel blockers: Novel class III antiarrhythmic agents. Bioorg. Med. Chem. Lett., 14: 4771-4777.
9. Cianchetta, G, Li, Y, Kang, J, Rampe, D, Fravolini, A, Cruciani, G and Vaz, RJ. 2005. Predictive models for hERG potassium channel blockers. Bioorg. Med. Chem. Lett., 15: 3637-3642.
10. Yoshida, K and Niwa, T. 2006. Quantitative structure-activity relationship studies on inhibition of hERG potassium channels. J. Chem. Inf. Model., 46: 1371-1378.
11. Seierstad, M and Agrafiotis, DK. 2006. A QSAR model of hERG binding using a large, diverse, and internally consistent training set. Chem. Biol. Drug Des., 67: 284-296.
12. Beshore, DC, Liverton, NJ, McIntyre, CJ, Claiborne, CF, Libby, B, Culberson, JC, Salata, JJ, Regan, CP, Lynch, JJ, Kiss, L, Spencer, R, Kane, SS, White, RB, Yeh, S, Hartman, GD and Dinsmore, CJ. 2010. Discovery of triarylethanolamine inhibitors of the Kv1.5 potassium channel. Bioorg. Med. Chem. Lett., 20: 2493-2496.
13. Bilodeau, MT, Balitza, AE, Koester, TJ, Manley, PJ, Rodman, LD, Buser-Doepner, C, Coll, KE, Fernandes, C, Gibbs, JB, Heimbrook, DV, Huckle, WR, Kohl, N, Lynch, JJ, Mao, X, McFall, RC, McLoughlin, D, Miller-Stein, C, Rickert, KW, Seep-Lorenzino, L, Shipman, JM, Subramanian, R, Thomas, KA, Wong, BK, Yu, S and Hartman, GD. 2004. Potent N-(1,3-thiazol-2-yl)pyridine-2-amine vascular endothelial growth factor receptor tyrosine kinase inhibitors with excellent pharmacokinetics and low affinity for hERG ion channel. J. Med. Chem., 47: 6363-6372.
14. Sato, N, Ando, M, Ishikawa, S, Jitsuoka, M, Nagai, K, Takahashi, H, Sakuraba, A, Tsuge, H, Kitazawa, H, Iwassa, H, Mashiko, S, Gomori, A, Moriya, R, Fujino, N, Ohe, T, Ishihara, A, Kanatani, A and Fukami, T. 2009. Discovery of tetrasubstituted imidazolines as potent and selective neuropeptide Y Y5 receptor antagonists: Reduced human ether-a-go-go related gene potassium channel binding affinity and potent antiobesity effect. J. Med. Chem., 52: 3385-3396.
15. Lin, A. QuaSAR-descriptors, J. Chem. Comput. Group. (2002). Available atwww.chemcomp.com/journal/descr.htm
16. Moorthy, NSHN, Ramos, MJ and Fernandes, PA. 2011. Analysis of α-glucosidase inhibitory activity of chromenone derivatives by its molecular features: A computational study. Med. Chem., 7: 526-533.
17. 2. J. Mol. Graph. Model., 20: 269-276.
18. Roy, PP and Roy, K. 2008. On some aspects of variable selected for partial least squares regression models. QSAR Comb. Sci., 27: 302-313.
19. Moorthy, NSHN, Sousa, SF, Ramos, MJ and Fernandes, PA. 2011. Structural feature study of benzofuran derivatives as farnesyltransferase inhibitors. J. Enz. Inhibit. Med. Chem., 26: 777-791.
20. Kiralj, R and Ferreira, MMC. 2009. Basic validation procedures for regression models in QSAR and QSPR studies: Theory and applications. J. Braz. Chem. Soc., 20: 770-787.
21. Guha, R and Van Drie, JH. 2008. Structure-activity landscape index: Identifying and quantifying activity cliffs. J. Chem. Inf. Model., 48: 646-658.
22. Wawer, M, Peltason, L and Bajorath, J. 2009. Elucidation of structure-activity relationship pathways in biological screening data, J. Med. Chem., 52: 1075-1080.
23. Peltason, L and Bajorath, J. 2007. SAR index: Quantifying the nature of structure-activity relationships. J. Med. Chem., 50: 5571-5578.
24. Gramatica, P. 2007. Principle of QSAR model validation: Internal and external. QSAR Comb. Sci., 26: 694-701.
25. Cook, R. 1979. Dennis, influential observation in linear regression. J. Am. Stat. Assoc., 74: 169-174.
26. Moorthy, NSHN, Cerquira, NM, Ramos, MJ and Fernandes, PA. QSAR analysis of 2-benzoxazolyl hydrazone derivatives for anticancer activity and its possible target prediction, Med. Chem. Res. 21 (2012), pp. 133-144. DOI: 10.1007/s00044-010-9510-3
27. Moorthy, NSHN, Ramos, MJ and Fernandes, PA. 2011. QSAR analysis of isosteviol derivatives as α-glucosidase inhibitors with element count and other descriptors. Lett. Drug Des. Dis., 8: 14-25.
28. Durbin, J and Watson, GS. 1950. Testing for serial correlation in least squares regression 1. Biometrika, 37: 409-428.
29. Cruciani, C, Crivori, P, Carrupt, PA and Testa, B. 2000. Molecular fields in quantitative structure-permeation relationships: The VolSurf approach. J. Mol. Struct. (Theochem), 503: 17-30.
30. Moorthy, NSHN, Ramos, MJ and Fernandes, PA. 2011. Structural analysis of α-glucosidase inhibitors by validated QSAR models using topological and hydrophobicity based descriptors. J. Chemometr. Intell. Lab. Syst., 109: 101-112.
31. Cruciani, G, Pastor, M and Guba, W. 2000. VolSurf, a new tool for the pharmacokinetic optimization of lead compounds. Eur. J. Pharm. Sci., 11: S29-S39.
32. Moorthy, NSHN, Cerqueira, NMFS, Ramos, MJ and Fernandes, PA. QSAR and pharmacophore analysis of thiosemicarbazone derivatives as ribonucleotide reductase inhibitors, Med. Chem. Res. (2011), DOI: 10.1007/s00044-011-9580-x
33. Moorthy, NSHN, Sousa, SF, Ramos, MJ and Fernandes, PA. 2011. In silico based structural analysis of arylthiophene derivatives for FTase inhibitory activity, hERG and other toxic effects4. J. Biomol. Screen., 16: 1037-1046.
34. Moorthy, NSHN, Ramos, MJ and Fernandes, PA. 2011. hERG binding feature analysis of structurally diverse compounds by QSAR and fragmental analysis. RSC Adv., 1: 1126-1136.
35. Moorthy, NSHN, Ramos, MJ and Fernandes, PA. Structural analysis of 2-piperidin-4-yl-actamide derivatives for hERG blocking and MCH R1 antagonistic activities, Curr. Drug Dis. Tech. 9 (2012),pp. 25-38